Incyte Reports P-III Study (TRuE-AD3) Results of Opzelura (ruxolitinib) for Children with Atopic Dermatitis
Shots:
- The P-III study (TRuE-AD3) evaluating Opzelura (selective JAK1/JAK2 inhibitor) vs vehicle in 300 patients aged ≥2-<12yrs. with AD
- The study met its 1EPs i.e., patients achieved IGA-TS (0.75% vs 1.5%). The overall safety profile was consistent with previous data with no new safety signals while the long-term safety portion of the study will continue as planned
- The therapy was approved in the US for the topical treatment of nonsegmental vitiligo in patients aged ≥12yrs. & for the topical short-term and non-continuous chronic treatment of mild to mod. AD in non-immunocompromised patients & is also approved in the EU for non-segmental vitiligo with facial involvement in adults and adolescents
Ref: Businesswire | Image: Incyte
Related News:- Incyte Presents P-II Trial (SCRATCH-AD) Results of Opzelura (ruxolitinib) for the Treatment of Atopic Dermatitis at RAD 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
